Ran Karmi

Dr. Ran Karmi is a member of the firm’s Antitrust and Competition Department.

Ran advises both Israeli and foreign corporations on mergers and acquisitions, dominant and monopolistic status, restrictive arrangements, and tender agreements.

Ran represents the firm’s clients before the Israel Competition Authority, the Competition Tribunal, and all levels of Israeli courts in proceedings involving antitrust and competition matters, as well as in other commercial litigation.

He boasts extensive previous experience as an attorney specializing in intellectual property and its regulation.

Ran served as an antitrust research assistant to Professor Michal S. Gal and an intellectual property research assistant to Professor Niva Elkin-Koren, both at the University of Haifa. During the course of his studies at the University of Haifa, Ran served as chief counsel of the Student Union and took part in numerous and diverse academic projects.

Ran was awarded a Ph.D. in Law from Bar-Ilan University in 2025, with a dissertation on enhanced damages in contract law.

Prominent legal directory The Legal 500 ranks Ran as a Recommended Lawyer in Competition and Antitrust.

Prior to joining Barnea, Ran served in the antitrust and competition department of a boutique law firm.

Education:

University of Haifa, LL.M., Law and Technology Program (2nd in his class), 2011

University of Haifa, LL.B. (magna cum laude and Dean's List), 2011

University of Haifa, B.A. in Economics, 2011

Bar-Ilan University, Ph.D. in Law (Dissertation on Enhanced Damages in Contract Law), 2025

Admission:

Israel Bar Association, 2012

Insights & News - Ran Karmi:

October 16, 2025

President Trump Imposes New Tariffs, Once Again Sowing Economic Chaos

The United States President recently announced the imposition of new 25% to 100% tariffs on pharmaceuticals, heavy-duty trucks, upholstered furniture, and kitchen and bathroom cabinets. The move is rocking markets and is likely to impact shipping costs, the furniture industry, and trade relations with various trading partners. It could also affect Israeli companies in various sectors.

Increased Enforcement in Pharmaceutical Sector: BMS and Neopharm to Pay ILS Tens of Millions for Delaying Entry of Competing Drug

The Israel Competition Authority (ICA) published a draft consent decree with Bristol-Myers Squibb and Neopharm, requiring payments of over ILS 44 million by the companies and ILS 200,000 by a Neopharm executive, following indications of monopolistic abuse.

US Court Rules: Most of Trump’s Tariffs Unlawful

The US Federal Court of Appeals ruled recently that most of the tariffs imposed by US President Donald Trump as part of the trade wars are unlawful. However, the court decided that, for the time being, these tariffs will remain in effect. This is a landmark decision with potentially wide-ranging implications for the US and global economies, as well as for the balance of powers within the US federal government.

See all news updates from Ran Karmi >

Practice areas:

Antitrust and Competition